WO1998010771A8 - Prevention of ovarian cancer by administration of progestin products - Google Patents

Prevention of ovarian cancer by administration of progestin products

Info

Publication number
WO1998010771A8
WO1998010771A8 PCT/US1997/016601 US9716601W WO9810771A8 WO 1998010771 A8 WO1998010771 A8 WO 1998010771A8 US 9716601 W US9716601 W US 9716601W WO 9810771 A8 WO9810771 A8 WO 9810771A8
Authority
WO
WIPO (PCT)
Prior art keywords
ovarian cancer
administration
prevention
products
progestin products
Prior art date
Application number
PCT/US1997/016601
Other languages
French (fr)
Other versions
WO1998010771A1 (en
Inventor
Gustavo C Rodriguez
Claude Hughes
Original Assignee
Univ Wake Forest
Gustavo C Rodriguez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wake Forest, Gustavo C Rodriguez filed Critical Univ Wake Forest
Priority to CA002265697A priority Critical patent/CA2265697A1/en
Priority to AU44242/97A priority patent/AU4424297A/en
Priority to EP97942565A priority patent/EP0929304A1/en
Publication of WO1998010771A1 publication Critical patent/WO1998010771A1/en
Publication of WO1998010771A8 publication Critical patent/WO1998010771A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems

Abstract

The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering progestin products, either alone or in combination with other agents such as estrogen products.

Description

FOR THE PURPOSES OF INFORMATION ONLY
Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.
AL Albania ES Spain LS Lesotho SI Slovenia
AM Armenia FI Finland LT Lithuania SK Slovakia
AT Austria FR France LU Luxembourg SN Senegal
AU Australia GA Gabon LV Latvia sz Swaziland
AZ Azerbaijan GB United Kingdom MC Monaco TD Chad
BA Bosnia and Herzegovina GE Georgia MD Republic of Moldova TG Togo
BB Barbados GH Ghana MG Madagascar TJ Tajikistan
BE Belgium GN Guinea MK The former Yugoslav TM Turkmenistan
BF Burkina Faso GR Greece Republic of Macedonia TR Turkey
BG Bulgaria HU Hungary ML Mali TT Trinidad and Tobago
BJ Benin IE Ireland MN Mongolia UA Ukraine
BR Brazil IL Israel MR Mauritania UG Uganda
BY Belarus IS Iceland MW Malawi us United States of America
CA Canada IT Italy MX Mexico uz Uzbekistan
CF Central African Republic JP Japan NE Niger VN Viet Nam
CG Congo KE Kenya NL Netherlands YU Yugoslavia
CH Switzerland KG Kyrgyzstan NO Norway ZW Zimbabwe
CI Cδte d'lvoire KP Democratic People's NZ New Zealand
CM Cameroon Republic of Korea PL Poland
CN China KR Republic of Korea PT Portugal
CU Cuba KZ Kazakstan RO Romania
CZ Czech Republic LC Saint Lucia RU Russian Federation
DE Germany LI Liechtenstein SD Sudan
DK Denmark LK Sri Lanka SE Sweden
EE Estonia LR Liberia SG Singapore
PCT/US1997/016601 1996-09-13 1997-09-12 Prevention of ovarian cancer by administration of progestin products WO1998010771A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002265697A CA2265697A1 (en) 1996-09-13 1997-09-12 Prevention of ovarian cancer by administration of progestin products
AU44242/97A AU4424297A (en) 1996-09-13 1997-09-12 Prevention of ovarian cancer by administration of progestin products
EP97942565A EP0929304A1 (en) 1996-09-13 1997-09-12 Prevention of ovarian cancer by administration of progestin products

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/713,834 US6028064A (en) 1996-09-13 1996-09-13 Prevention of ovarian cancer by administration of progestin products
US08/713,834 1996-09-13

Publications (2)

Publication Number Publication Date
WO1998010771A1 WO1998010771A1 (en) 1998-03-19
WO1998010771A8 true WO1998010771A8 (en) 2000-09-28

Family

ID=24867726

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/016601 WO1998010771A1 (en) 1996-09-13 1997-09-12 Prevention of ovarian cancer by administration of progestin products

Country Status (5)

Country Link
US (4) US6028064A (en)
EP (1) EP0929304A1 (en)
AU (1) AU4424297A (en)
CA (1) CA2265697A1 (en)
WO (1) WO1998010771A1 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
US20040167106A1 (en) * 1993-06-04 2004-08-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of a Vitamin D compound
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
JP2002509888A (en) * 1998-03-27 2002-04-02 オレゴン ヘルス サイエンシーズ ユニバーシティー Vitamin D and its analogs in the treatment of tumors and other hyperproliferative diseases
WO2001024826A2 (en) * 1999-10-06 2001-04-12 The Brigham And Women's Hospital, Inc. Inrease of enos activity through activation of the pi3-kinase/akt pathway by estrogens
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US6585391B1 (en) 2000-05-31 2003-07-01 Nordic Technologies, Inc. Flashlight and flashlight electrical connectors
US6867238B2 (en) * 2001-06-22 2005-03-15 Gerhard N. Schrauzer Compositions for the treatment and prevention of cancer
NZ555299A (en) * 2001-12-05 2008-10-31 Duramed Pharmaceuticals Inc Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US20090163454A1 (en) * 2003-05-02 2009-06-25 Duramed Pharmaceuticals, Inc. Methods of Step-Down Hormone Treatment
JP2006525358A (en) * 2003-05-02 2006-11-09 ドゥラメド ファーマシューティカルズ， インコーポレイテッド Hormonal therapy using long-term contraceptive regimen
AU2004257772B2 (en) * 2003-07-16 2009-12-17 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
US20050113350A1 (en) * 2003-11-26 2005-05-26 Bernd Duesterberg Extended use combination comprising estrogens and progestins
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
EP2392332A1 (en) * 2004-10-07 2011-12-07 Teva Women's Health, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
WO2006052952A2 (en) * 2004-11-09 2006-05-18 The Brigham And Women's Hospital, Inc. System and method for determining whether to issue an alert to consider prophylaxis for a risk condition
US7579782B2 (en) * 2004-12-07 2009-08-25 Mag Instrument, Inc. Circuitry for portable lighting devices and portable rechargeable electronic devices
US7723921B2 (en) * 2004-12-07 2010-05-25 West Stacey H Circuitry for portable lighting devices and portable rechargeable electronic devices
WO2007076144A2 (en) * 2005-12-27 2007-07-05 Duramed Pharmaceuticals, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
EP2422800A3 (en) 2006-03-07 2013-03-06 Geeta Shroff Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
NZ611268A (en) * 2008-02-04 2015-03-27 Teva Women’S Health Inc Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
US20100022494A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
US20100022497A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject
US20100022991A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System and device for maintaining physiological levels of steroid hormone in a subject
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX2016014281A (en) 2014-05-22 2017-02-22 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
EP3275888B1 (en) 2016-07-28 2019-09-25 Council of Scientific & Industrial Research Progesterone-cationic lipid hybrid as anticancer agent and the process of synthesis thereof
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3608075A (en) 1969-07-28 1971-09-21 American Home Prod Compositions and methods of treating the menopausal syndrome
US3969502A (en) 1972-04-14 1976-07-13 Schering Aktiengesellschaft Method for contraception by the administration of sequential contraceptive preparations
DE2365103C3 (en) 1973-12-21 1980-08-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Use of hormones for contraception
US4390531A (en) 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
US4921843A (en) 1988-10-20 1990-05-01 Pasquale Samuel A Contraception system and method
US4544554A (en) 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4616006A (en) 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4628051A (en) 1983-09-26 1986-12-09 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4530839A (en) 1983-09-26 1985-07-23 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
DE3347125A1 (en) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen MULTI-STAGE COMBINATION PREPARATION AND ITS USE FOR ORAL CONTRACTION
US4931283A (en) 1983-12-22 1990-06-05 American Home Products Corp. (Del) Menthol enhancement of transdermal drug delivery
US4933184A (en) 1983-12-22 1990-06-12 American Home Products Corp. (Del) Menthol enhancement of transdermal drug delivery
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4962098A (en) 1987-06-15 1990-10-09 Warner-Lambert Company Graduated estrogen contraceptive
US4594340A (en) 1984-11-29 1986-06-10 Hoffmann-La Roche Inc. 25,26-dehydro-1α,24R-dihydroxycholecalciferol and 25,26-dehydro-1α,24S-dihydroxycholecalciferol and the epimeric mixture
GB8503940D0 (en) * 1985-02-15 1985-03-20 Erba Farmitalia 4-substituted androstendione derivatives
US4800198A (en) 1985-04-23 1989-01-24 Wisconsin Alumni Research Foundation Method of inducing the differentiation of malignant cells with secosterol
GB8517360D0 (en) * 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
US4817819A (en) 1985-12-19 1989-04-04 Berlex Laboratories, Inc. Container for tablets
GB8531747D0 (en) * 1985-12-24 1986-02-05 Erba Farmitalia 10beta-alkynylestrene derivatives
GB8615092D0 (en) * 1986-06-20 1986-07-23 Erba Farmitalia Androst-4-ene-317-diones
DK174724B1 (en) 1986-07-15 2003-10-06 Wyeth Corp Use of a composition comprising an estrogen and a progestogen for the preparation of a dosage form to provide hormone replacement therapy and contraception for women during the premenopause and pack to provide the composition
DE3625315A1 (en) * 1986-07-25 1988-01-28 Schering Ag 11SS- (4-ISOPROPENYLPHENYL) -ESTRA-4,9-DIENES, THEIR PRODUCTION AND THE PHARMACEUTICAL PREPARATIONS CONTAINING THEM
DE3702383A1 (en) * 1987-01-23 1988-08-04 Schering Ag 11SS-ALKINYLESTRENE AND -ESTRADIENE, THEIR PRODUCTION AND THEIR PHARMACEUTICAL PREPARATIONS CONTAINING THEM
US4855305A (en) * 1987-03-23 1989-08-08 Applied Medical Research Compositions and methods of effecting contraception utilizing melatonin
US5108995A (en) 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
US5276022A (en) 1987-09-24 1994-01-04 Jencap Research Ltd. Hormone preparation and method
US5256421A (en) 1987-09-24 1993-10-26 Jencap Research Ltd. Hormone preparation and method
US5422119A (en) 1987-09-24 1995-06-06 Jencap Research Ltd. Transdermal hormone replacement therapy
BE1004905A4 (en) * 1987-12-30 1993-02-23 Roussel Uclaf NOVEL 17BETA-OH 19-NOR DERIVATIVES SUBSTITUTED IN 17ALPHA, THEIR PREPARATION PROCESS, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US4780497A (en) 1988-02-12 1988-10-25 The B. F. Goodrich Company Reduced melt viscosity CPVC blends containing sulfur and various metal carbonate stabilizers
AU614372B2 (en) 1988-04-21 1991-08-29 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Novel vitamin d analogues
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
US5364847A (en) * 1989-03-10 1994-11-15 Endorecherche Inhibitors of sex steroid biosynthesis and methods for their production and use
US5401731A (en) 1989-06-29 1995-03-28 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Productionsaktieselskab) Vitamin D analogues
GB8915770D0 (en) 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
US4954790A (en) * 1989-11-15 1990-09-04 Avantek, Inc. Enhanced coupled, even mode terminated baluns, and mixers and modulators constructed therefrom
FR2656309B1 (en) * 1989-12-22 1992-05-07 Roussel Uclaf NEW STEROUID PRODUCTS COMPRISING IN POSITION 10, A SUBSTITUTED ETHYL RADICAL, THEIR PREPARATION METHOD, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
GB8929059D0 (en) 1989-12-22 1990-02-28 Leo Pharm Prod Ltd Chemical compounds
FR2656310B1 (en) * 1989-12-22 1992-05-07 Roussel Uclaf NEW STEROUID PRODUCTS COMPRISING IN POSITION 10, A SUBSTITUTED THIOETHYL RADICAL, THEIR PREPARATION METHOD AND THE INTERMEDIATES THEREOF, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5532228A (en) 1990-02-06 1996-07-02 Schering Aktiengesellschaft Side-chain homologous vitamin D derivatives, process for their production, pharmaceutical preparations containing these derivatives and their use as pharmaceutical agents
US5227375A (en) * 1990-02-08 1993-07-13 Endorecherche, Inc. Aromatase inhibitors
GB9007236D0 (en) 1990-03-30 1990-05-30 Leo Pharm Prod Ltd Chemical compounds
US5314694A (en) 1990-10-29 1994-05-24 Alza Corporation Transdermal formulations, methods and devices
IE71203B1 (en) 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
IE62665B1 (en) 1990-12-17 1995-02-22 Akzo Nv Contraceptive regimen
IE71202B1 (en) * 1990-12-17 1997-02-12 Akzo Nv Progestagen-only contraceptive
AU665341B2 (en) * 1990-12-18 1996-01-04 Wellcome Foundation Limited, The Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
DE4101953A1 (en) 1991-01-19 1992-07-23 Schering Ag 23-OXA DERIVATIVES IN THE VITAMIN-D SERIES, METHOD FOR THE PRODUCTION THEREOF THE PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES AND THE USE THEREOF AS MEDICINAL PRODUCTS
CH681153A5 (en) * 1991-01-28 1993-01-29 Marigen S.A. New and sterolester- sterolphosphorverbindungen.
DE4104385C1 (en) 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich
US5278155A (en) 1991-06-05 1994-01-11 Daikin Industries, Ltd. Fluorine-containing vitamin D3 analogues and cell differentiation-inducing agent containing the same
HU222501B1 (en) * 1991-06-28 2003-07-28 Endorecherche Inc. Controlled release pharmaceutical composition containing mpa or mga and process for its preparation
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
DE4141746A1 (en) 1991-12-13 1993-06-17 Schering Ag 20-METHYL-SUBSTITUTED VITAMIN D DERIVATIVES
US5210081A (en) 1992-02-26 1993-05-11 American Home Products Corporation Alkali metal 8,9-dehydroestrone sulfate esters
US5274142A (en) 1992-03-12 1993-12-28 The Johns Hopkins University Vitamin D3 analogues
CA2096105A1 (en) 1992-10-07 1994-04-08 Enrico Giuseppe Baggiolini (Deceased) Vitamin d3 fluorinated analogs
GB9226877D0 (en) 1992-12-23 1993-02-17 Leo Pharm Prod Ltd Chemical compounds
CA2118317A1 (en) * 1993-02-18 1994-09-01 Pharmacia S.P.A. Fluorinated 4-aminoandrostadienone derivatives and process for their preparation
US5468736A (en) 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
US5547947A (en) 1993-03-11 1996-08-20 Hoffmann-La Roche Inc. Methods of treatment
DE69400495T2 (en) 1993-04-05 1997-04-30 Wisconsin Alumni Res Found 19-nor-vitamin D3 compound with a substituent in the 2nd position
US5380720A (en) 1993-05-11 1995-01-10 Wisconsin Alumni Research Foundation Iodo vitamin D3 compounds and method for preparing same
US5486511A (en) * 1993-05-25 1996-01-23 Merrell Dow Pharmaceuticals Inc. 4-amino-17β-(cyclopropyloxy)androst-4-en-3-one, 4-amino-17β-(cyclopropylamino)androst-4-en-3-one and related compounds as C17-20 lyase and 5α-reductase
US5595970A (en) 1993-07-16 1997-01-21 Schering Aktiengesellschaft Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors
US5565589A (en) 1993-11-03 1996-10-15 Wisconsin Alumni Research Foundation 17-formyl-5,6-trans-vitamin D compounds
US5373004A (en) 1993-11-24 1994-12-13 Wisconsin Alumni Research Foundation 26,28-methylene-1α, 25-dihydroxyvitamin D2 compounds
US5428029A (en) 1993-11-24 1995-06-27 Hoffmann-La Roche Inc. Vitamin D3 fluorinated analogs
DE4344462C2 (en) * 1993-12-22 1996-02-01 Schering Ag Composition for contraception
US5811416A (en) 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
US5633011A (en) 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
IL115659A (en) 1994-10-27 2000-06-01 Akzo Nobel Nv Steroids with a 17-spiromethylene lactone or lactol group process for their preparation and pharmaceutical compositions containing them
IL116433A (en) 1994-12-19 2002-02-10 Galen Chemicals Ltd INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE ADMINISTRATION OF 17β-OESTRADIOL PRECURSORS
AU703593B2 (en) 1995-06-07 1999-03-25 Ortho-Mcneil Pharmaceutical, Inc. Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
US5922349A (en) 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
EP0889972B1 (en) 1996-01-17 2007-06-13 Sequenom-Gemini Limited Use of the determination of polymorphims in the promoter region of the TGF-beta 1 gene in diagnosis
GB9604305D0 (en) 1996-02-29 1996-05-01 Ralston Stuart H Diagnostic method and apparatus
US5898038A (en) 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
US5827876A (en) 1996-04-09 1998-10-27 American Home Products Corporation Inhibition of bone loss by 3-(4-acrylamidobenzoyl) benzo b!-thiophenes
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5985910A (en) 1996-04-19 1999-11-16 American Home Products Corporation 3- [4- (2- Phenyl-Indole-1-ylmethyl) Phenyl]- Acrylamides as estrogenic agents
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5747480A (en) 1996-05-08 1998-05-05 American Home Products Corporation Oral contraceptive
US5783208A (en) 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5888543A (en) 1996-07-26 1999-03-30 American Home Products Corporation Oral contraceptives
US5858405A (en) 1996-07-26 1999-01-12 American Home Products Corporation Oral contraceptive
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US5994337A (en) 1997-01-13 1999-11-30 Wake Forest University Effects of 17α-dihydroequilenin on plasma lipid and lipoprotein, glucose, insulin concentrations, coronary artery vasomotor function, and reproductive organ and mammary gland proliferation in atherosclerotic mammals
US5948775A (en) 1997-03-19 1999-09-07 American Home Products Corporation 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones
US5891868A (en) 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen
US6001846A (en) 1998-02-17 1999-12-14 Ligand Pharmaceuticals Incorporated Process for the preparation of 1,2-dihydroquinolines
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US5962444A (en) 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties

Also Published As

Publication number Publication date
US20020028795A1 (en) 2002-03-07
US6319911B1 (en) 2001-11-20
WO1998010771A1 (en) 1998-03-19
CA2265697A1 (en) 1998-03-19
US6028064A (en) 2000-02-22
US6977250B2 (en) 2005-12-20
EP0929304A1 (en) 1999-07-21
AU4424297A (en) 1998-04-02
US6310054B1 (en) 2001-10-30

Similar Documents

Publication Publication Date Title
WO1998010771A8 (en) Prevention of ovarian cancer by administration of progestin products
WO1999045910A3 (en) Methods and compositions for treating and preventing mucositis
WO1998023046A8 (en) High margin notification method and apparatus
WO1998010386A8 (en) Disc-like device with eas material
WO1998024183A8 (en) Mouse interface device for providing force feedback
WO1997048032A8 (en) Programmable metallization cell and method of making
WO1997025042A8 (en) Use of an agonist of ppar-alpha and ppar-gamma for the treatment of syndrom x
WO1998000479A8 (en) Raffinate hydroconversion process
WO1998018888A8 (en) Refining of edible oil rich in natural carotenes and vitamin e
WO1998023050A3 (en) Simultaneous over the air data download to multiple receivers
WO1999015684A8 (en) Expression of genes in hematopoietic stem cells in hischaemic conditions
WO1998016421A8 (en) Aircraft based sensing, detection, targeting, communications and response apparatus
WO1998016077A8 (en) Communication system using geographic position data
WO1998015622A8 (en) Transformation and regeneration of fertile cotton plants
WO1997020575A8 (en) Targeted adenovirus vectors
WO1998022094A3 (en) Method for producing shaped and unshaped polyol masses
WO1998032048B1 (en) Optical waveguide amplifier
WO1998017782A8 (en) Method for producing transgenic animal models with modulated phenotype and animals produced therefrom
WO1998009686A8 (en) Hydrobromocarbon blends to protect against fires and explosions
WO1998025264A8 (en) Leading edge slider microactuator
WO1998040762B1 (en) Image-directed active range finding system
WO1997017980A8 (en) Treatment of cardiomyopathy by removal of autoantibodies
WO1998015272A8 (en) Method for inhibiting stress-activated protein kinases
WO1998023962A8 (en) Diagnosis of prion diseases
WO1996001622A8 (en) New oral pharmaceutical formulation containing magnesium salt of omeprazole

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN JP MX AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2265697

Country of ref document: CA

Ref country code: CA

Ref document number: 2265697

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997942565

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998514002

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1997942565

Country of ref document: EP

AK Designated states

Kind code of ref document: C1

Designated state(s): AU BR CA CN JP MX

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
WWW Wipo information: withdrawn in national office

Ref document number: 1997942565

Country of ref document: EP